The ongoing regulation of generic drugs

New England Journal of Medicine

Volumn 357, Issue 20, 2007, Pages 1993-1996

  Frank, Richard G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE BESYLATE; GENERIC DRUG; RISPERIDONE; SUMATRIPTAN SUCCINATE;

CONSUMER; DRUG COMPETITION; DRUG COST; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; LEGAL ASPECT; PATENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

EID: 36148940587     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078193     Document Type: Article

References (3)

1. Silver R. A Wall Street perspective on generics. Presented at the 2007 GPhA Annual Meeting, Phoenix, March 1-3, 2007.
2. IMS Health. Generics market expected to soar to $80 billion by 2008. (Accessed October 25, 2007, at http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_40183881_52651243,00.html.)
3. District US. Court for the District of Columbia. Order and stipulated permanent injunction. (Accessed October 25, 2007, at http://www.ftc.gov/os/2000/ 11/mylanordandstip.htm.)